Neutrexin trimetrexate data

University researchers presented data at the American Society of Clinical Oncology meeting in Philadelphia, showing that the combination of Neutrexin (110 mg/m 2) with leucovorin and 5-fluorouracil (5-FU) was effective in treating unresectable or metastatic colorectal cancer.

A Phase II study enrolled 36 patients, of whom 29 were evaluable for response. Two patients had a complete response and 12 had a partial response, for an overall response rate of 48 percent. Median follow-up is now 14 months and patients haven't yet reached median survival. ...